BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18243501)

  • 1. Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
    Kassouf W
    Eur Urol; 2008 Oct; 54(4):853-4. PubMed ID: 18243501
    [No Abstract]   [Full Text] [Related]  

  • 2. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
    Lee SJ; Lattouf JB; Xanthopoulos J; Linehan WM; Bottaro DP; Vasselli JR
    Eur Urol; 2008 Oct; 54(4):845-53. PubMed ID: 18243508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal cancer genetics: von Hippel Lindau and other syndromes.
    Fleming S
    Int J Dev Biol; 1999; 43(5):469-71. PubMed ID: 10535326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic backgrounds of renal cell carcinoma].
    Oya M
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():593-6. PubMed ID: 16523961
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic loss analysis of tumor suppressor genes regardless of heterozygosity: von Hippel-Lindau gene loss in renal cell carcinoma.
    Mochida J; Esumi M; Kitajima A; Okada K
    J Urol; 2008 Aug; 180(2):724-8. PubMed ID: 18554638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIFing the brakes: therapeutic opportunities for treatment of human malignancies.
    Garcia JA
    Sci STKE; 2006 May; 2006(337):pe25. PubMed ID: 16738063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A family of von Hippel-Lindau disease with renal cell carcinoma--case report and review of the literature].
    Ito F; Uda M; Toma H
    Hinyokika Kiyo; 1991 Feb; 37(2):157-62. PubMed ID: 2048495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
    Richard S
    Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 19. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
    Chen F; Kishida T; Duh FM; Renbaum P; Orcutt ML; Schmidt L; Zbar B
    Cancer Res; 1995 Nov; 55(21):4804-7. PubMed ID: 7585510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms?
    Siroky BJ; Czyzyk-Krzeska MF; Bissler JJ
    Nat Clin Pract Nephrol; 2009 Mar; 5(3):143-56. PubMed ID: 19240728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.